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M. Pardo2,4, A. B. Crujeiras2,4, R. Granero2,5, R. Baños2,6, C. Botella2,7, R. de la Torre2,8, 
J. M. Fernández-Real2,9, J. C. Fernández-García2,10, G. Frühbeck2,11, A. Rodríguez2,11, 
N. Mallorquí-Bagué1,2, S. Tárrega5, F. J. Tinahones2,10, R. Rodriguez9, F. Ortega2,9,  
J. M. Menchón1,3,12, F. F. Casanueva2,4 & F. Fernández-Aranda1,2,3
Whether the executive profile is different between obesity (OB) and morbid obesity (MO) remains 
unclear. Recent evidence suggests that physical activity (PA) can act as a cognitive enhancer. Irisin is a 
recently discovered hormone associated with some of the positive effects of PA. The objective of the 
study was to investigate the executive profile in OB and MO, and to explore the role of PA and irisin. 114 
participants were included (21 OB, 44 MO and 49 healthy controls-HC) in the study and assessed with 
the Wisconsin Card Sorting Test, Stroop Color and Word Test, and Iowa Gambling Task. All participants 
were female, aged between 18 and 60 years. Results showed a similar dysfunctional profile on decision 
making in OB and MO compared with HC. Thus, no specific neuropsychological profiles between OB and 
MO can be clearly observed in our sample. However, a negative correlation was found between irisin 
and executive functioning. These results demonstrate a specific executive profile in OB and a relevant 
and negative modulation of irisin on executive functioning. Although irisin might be a promising target 
for the treatment of obesity, its effects on cognition might be considered when thinking about its 
therapeutic use.
Obesity has been associated with important biological and environmental risk factors1. It has been demonstrated 
that these patients have a dysfunctional neural pattern, characterized by an alteration in the brain circuitry associ-
ated with the reward system2–4. From a neuropsychological perspective, deficits in attention, memory and mainly 
executive functions are major domains defining this pathology5. In a previous study, we have demonstrated a 
dysfunctional executive profile in obesity, mainly in the cognitive flexibility and decision making domains6. 
However, whether this cognitive profile differs between obese (BMI = 30–39.9 kg/m2), and morbid obese sub-
jects (BMI ≥ 40 kg/m2) remains unclear.
The mechanisms underlying the cognitive deficits in obesity are also poorly understood. Some hypotheses, 
concerning vascular and metabolic states associated with obesity, have been considered as influencing cognitive 
performance in obesity7–9. However, it is well-accepted that cognitive functions are complex and are influenced 
by a number of social and environmental factors10. In this line, recent evidence in both human and animal studies 
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suggests that exercise can act as a cognitive enhancer11–13. Of interest, the most important effects of physical 
activity appear to be on tests measuring executive functions such as response inhibition, working memory and 
decision making14.
Specifically, meta-analyses in humans indicate that physical exercise correlates positively with cognitive per-
formance in healthy subjects and in patients with dementia or mild cognitive impairment14–16. Recent neuroim-
aging studies also suggest that a combination of omega-3 fatty acids, aerobic exercise and cognitive stimulation 
prevents a decline in the gray matter volume of the frontal, parietal and cingulate cortex in patients with mild 
cognitive impairment17. Particularly interesting are those studies suggesting that physical activity, a balanced 
diet, cognitive stimulation or the management of conditions such as diabetes and obesity are preventive factors 
in Alzheimer’s disease18. Alongside pharmacological research, these approaches may help slow down the pro-
gression of the disease. However, in order to develop successful treatments that complement these strategies, the 
understanding of the underlying mechanisms is essential.
It has been postulated that irisin, a recently discovered hormone, might be associated with some of the effects 
of physical exercise such as energy expenditure and thermogenesis19, even though its role is far from being clear. 
Irisin is secreted after the cleaving of the membrane protein fibronectin type III domain containing 5 (FNDC5) 
and is related to the conversion of white adipose tissue into beige adipose tissue by means of its action in the 
expression of the uncoupling protein 1 (UCP1). Animal studies suggest that increased plasma levels of irisin are 
associated with an increase in energy expenditure19. In humans, irisin has been linked to body mass index (BMI) 
despite results being inconsistent. Some authors have reported a positive correlation between circulating irisin 
levels and BMI20–23, whereas others a negative correlation24,25. Some variables that can explain these differences 
are the methods used for measuring circulating levels of irisin and the presence of diabetes. Our results could be 
crucial since all published findings regarding irisin, and particularly circulating irisin levels, are actually under a 
cloud of suspicion26,27. At this point, as we have previously stated in a recent review28, there is no doubt as to the 
need to discern which fraction of FNDC5 is cleaved to produce the soluble portion of irisin. For these reasons, in 
this study we used the Phoenix pharmaceuticals ELISA kit Ref. EK-067-52, being the only available kit that has 
been validated20. Regardless, based on these findings, it might be postulated that irisin could be a target hormone 
in conditions characterized by pathological food intake and extreme BMI, such as obesity.
Additionally, previous reports have evidenced that irisin may have a role in the nervous system. This con-
clusion is based on the expression of FNDC5 in the brain29, as well as the presence of irisin in human cerebro-
spinal fluid and hypothalamic sections30. Thus, although it is currently unknown whether irisin can cross the 
blood-brain barrier and whether irisin may function as a messenger between the skeletal muscle or adipose 
tissue and brain, previous studies demonstrated that, for example, peripheral administration of irisin is able to 
reduce blood pressure induced by sympathetic out-flow31. Thus, considering the association between irisin levels 
and physical activity, it is reasonable to consider the role of this hormone on the cognitive effects of exercise in 
humans, especially taking into account their expression in the brain, as found in several animal studies29,32.
Thus, the objective of the study was to investigate differences in the cognitive profile of obese subjects versus 
that of morbid obese subjects, mainly in executive functioning (decision making, response inhibition and cog-
nitive flexibility). We also aimed at exploring the relationship between levels of physical activity and circulating 
levels of irisin and prefrontal-mediated executive functions in these patients. We hypothesized that both obese 
and morbid obese subjects would show alterations in executive performance compared to healthy controls. We 
also hypothesized a role of irisin levels on this dysexecutive profile. For this purpose, we used three neuropsycho-
logical tasks (Wisconsin Card Sorting Test; Stroop Color and Word Test; and Iowa Gambling Task) known to be 
mediated by the prefrontal and orbitofrontal cortex functioning33.
Results
Sample characteristics. Table 1 includes the descriptive data of the participants of the study. Statistically 
significant differences were observed across all variables. HC were the group with the highest proportion of 
university-level education while obese group presented the highest proportion of low academic levels. Mean age 
was statistically equal for OB and MO (p = 214) but patients of these two groups were statistically older than HC 
(p < 001 for both pairwise comparisons). Means for BMI and body-fat were higher for MO, followed by OB and 
HC (for these two variables linear and quadratic trends achieved significant results indicating that differences 
between MO vs OB were lower than those obtained for HC vs OB).
Group comparison for plasma irisin and activity levels. Table 2 contains the comparison between 
weight groups for circulating levels of irisin and activity levels (MVPA), adjusted by the covariates participants’ 
age and years of education. Regarding plasma irisin levels, a significant linear trend was obtained (means for irisin 
tended to increase comparing HC, OB and MO), but a quadratic trend was not statistically significant (mean 
difference for HC vs OB is similar to mean difference between OB and MO). All pairwise comparisons for plasma 
irisin levels were statistically significant and obtained moderate to high effect size (|d| > 0.50). With respect to 
activity levels, a linear trend was also achieved (means for MVPA tended to decrease comparing HC, OB and 
MO) and a quadratic trend was not significant. For MVPA, the only significant pairwise comparison with mod-
erate effect size was that of MO versus HC. Figure 1 shows the radar chart for the means of the z-scores of irisin 
and activity levels, illustrating that the morbidly obese group was characterized by the highest irisin levels and low 
MVPA-IGT levels, obese patients by medium MVPA-irisin levels and low IGT measures, while the control group 
by high IGT scores, medium MVPA and very low irisin levels.
Group comparison for neuropsychological performance. Table 3 depicts the ANOVA results com-
paring neuropsychological test performance between weight groups (HC, OB and MO), adjusted by patients’ age 
and years of education. Only the total IGT scores were different across the three diagnostic conditions: means 
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tended to decrease when comparing HC versus OB and MO (significant linear trend) and the statistical quad-
ratic trend indicates that the difference comparing HC versus OB (means 31.7 vs − 0.81) was higher than the 
difference of OB versus MO (means − 0.81 vs 3.40). Pairwise comparisons achieved significant results and a high 
effect size for HC compared to OB and MO, but no statistical differences were found upon comparing OB and 
MO. Figure 1 also included the distribution of means for z-IGT scores. No significant differences between groups 
were observed for the WCST. Lastly, the OB subjects displayed the worse performance in Stroop test (interference 
score), although no significant differences between the three groups were observed.
Association between irisin and activity levels with neuropsychological measures. Table 4 contains 
the partial correlations, adjusted by participants’ age and years of education, between irisin and MVPA with 
the cognitive outcomes. The r-coefficients were estimated separately (stratified) according to weight group. For 
HC, activity levels correlated positivity with the WCST-total correct items and negatively with the IGT total 
score, while irisin correlated negatively with interference and WCST-categories completed and positively with 
WCST-total errors. For OB, activity levels correlated positively with the IGT-total score and negatively with 
WCST total correct hits, conceptual answers and categories completed. No association was found between irisin 
levels and cognitive measures. For MO, the activity levels correlated positively with the interference measures 
(Stroop interference score) and negatively with the IGT-total score. Irisin levels also correlated negatively with 
the IGT total score.
Discussion
This study set out to examine the executive profile of obese and morbidly obese subjects and the role of irisin and 
activity on prefrontal-dependent cognitive functions in healthy controls and obese subjects. The primary finding 
of this study was the similar executive profile observed between obese and morbidly obese subjects. According 
to our results, neither obese nor morbidly obese patients showed significant impairment in the cognitive flexi-
bility capacity or the inhibition response compared to the healthy controls. However, they showed a significant 
impairment in the decision making capacity. Finally, although not statistically significant a moderate to high 
effect size of correlations between levels of irisin and physical activity with neuropsychological measures were 
found. Although physical activity has been previously related to executive functions12, this is to the best of our 
knowledge, the first time that not only physical activity, but also irisin is to some extent associated with executive 
functioning in humans.
As for decision making performance, both OB and MO subjects went for choices that result in elevated imme-
diate gains despite important future losses, thus showing a similar level of impairment. This profile has been 
previously described in obese patients6, suggesting that reduced decision making abilities are core characteristics 
of obesity and result in inadequate self-control6. Of interest, a recent systematic review examining the relation-
ship between obesity and cognition concluded that decision making is one of the functions most affected in these 
patients34. From a clinical perspective, it might be postulated that there are rational similarities between OB and 
MO subjects in terms of decision making performance and day to day eating behavior.
These neuropsychological results are also consistent with the hypothesis of food addiction in obesity4,35. 
According to this theory, the neural substrates of the decision making’s deficits in obesity are similar to those 
found in drug addiction. Specifically, previous results have suggested that executive functions, such as decision 
making, are modulated by dopaminergic functioning (D1 receptors and D2 receptors) in prefrontal cortex and 
fronto-subcortical circuits33. In human and animal models, it has been demonstrated that D2R downregulation 
mediates signaling in the striatal indirect circuits associated with prefrontal areas36. In addition, impairments in 
those circuits have been linked to less executive control37, thus suggesting that DA’s impaired modulation of these 
areas might be contributing to the impulsive drug intake seen in addiction38,39. In support, neuroimaging studies 
HC normal-weight 
(n = 49) Obesity (n = 21)
Morbid-Obesity 
(n = 44) Statistic p
Academic level; %
Primary 8.2% 70.6% 61.9%
χ 2(df:4) = 43.65 <0.001Secondary 38.8% 23.5% 31.0%
University 53.1% 5.9% 7.1%
Education (years);
Range 9 to 20 7 to 20 0 to 20
F(df:3;110) = 35.33 <0.001Mean (SD) 18.47 (2.52) 11.76 (3.82) 13.00 (4.70)
Age (years);
Range 19 to 46 26 to 68 22 to 63
F(df:3;110) = 42.31 <0.001Mean (SD) 29.04 (6.22) 49.19 (11.69) 42.25 (10.84)
BMI (kg/m2);
Range 18.97 to 24.61 30.79 to 39.11 40.35 to 59.52
F(df:3;110) = 624.4 <0.001Mean (SD) 21.61 (1.54) 35.52 (2.40) 46.32 (4.91)
Body-fat (%);
Range 18 to 35 34 to 50 38 to 53
F(df:3;110) = 287.3 <0.001Mean (SD) 26.57 (4.50) 41.41 (3.84) 46.55 (3.66)
Irisin (ng/ml);
Range 60.5 to 171.7 92.3 to 176.0 68.7 to 219.8
F(df:3;110) = 20.86 <0.001Mean (SD) 104.00 (24.32) 122.38 (23.63) 141.40 (32.96)
Activity: MVPA;
Range 14.0 to 154.2 9.0 to 151.5 3.7 to 126.8
F(df:3;110) = 5.04 0.008Mean (SD) 71.37 (34.09) 54.47 (43.82) 47.40 (34.15)
Table 1.  Sociodemographics, irisin and activity levels. BMI: Body mass index. SD: standard deviation.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:30820 | DOI: 10.1038/srep30820
in both drug addicted and obese subjects have evidenced low availability of D2R in the striatum to be associated 
with reduced activity in the ACC and deficient control over food and drug consumption40,41, which points to the 
similar brain deregulation in obesity and addiction.
However, we failed to find an association between obesity and inhibition response or cognitive flexibility. 
According to our results, the executive profile in obesity is more associated with impairments in ‘hot’ executive 
functions (related to emotional or motivational processes) than ‘cold’ executive functions (more rational or logical 
processes)42. Our results are not in line with those of other studies, showing alterations in cognitive flexibility and 
inhibition response in obesity5. These differences might be explained by the characteristics of the sample. A rele-
vant strength of our study is the exclusion of patients with eating disorders, such as Binge eating disorder (BED) 
or Bulima nervosa, and diabetes. It has been broadly demonstrated that obese patients with eating disorders or 
impaired glucose regulation show deficits in inhibition and flexibility43. Furthermore, it has been demonstrated 
that obese individuals with obesity-related somatic comorbidity (i.e., hypertension, diabetes) perform worse in 
neurocognitive tasks compared to obese individuals without any somatic disorder44. Additionally, neuroimaging 
studies have demonstrated that individuals with BED have a diminished ability to recruit impulse-control-related 
brain regions compared with obese subjects without BED. The authors concluded that the observed differences in 
neural correlates of inhibitory processing in BED relative to OB suggest distinct neurobiological contributions to 
binge eating as a subgroup of obese individuals45. All in all, these discrepant results highlight the importance of 
controlling for these confounder variables in cognitive studies, and conducting a more comprehensive assessment 
of inhibition response and cognitive flexibility in obesity.
The effects of activity in executive functions are in line with the positive effects of physical activity in other 
cognitive functions. It has been demonstrated that exercise positively activates cognitive performance11–13. In 
studies with healthy controls, physical activity has been positively correlated to improvements in executive func-
tions such as cognitive flexibility and working memory14,15. It has also been demonstrated that older adults that 
engage in physical exercise show a better performance in reasoning capacity, working memory and speed of pro-
cessing than those maintaining a sedentary lifestyle46. Similarly, physically active retired subjects perform better 
on a series of cognitive tests than retired individuals who are inactive47.
Adjusted means
Factor Group
Trends Pairwise-comparisons: mean differences
HC OB MO Linear Quadratic OB vs HC MO vs HC MO vs OB
n = 49 n = 21 n = 44 F(2;111) p F(1;111) p F(1;111) p MD p |d| MD p |d| MD p |d|
Irisin 
(ng/ml) 104.0 122.4 141.4 20.86 0.002 41.72 0.002 0.002 0.999 18.38 0.026 0.77* 37.40 0.002 1.29* 19.02 0.022 0.66* 
Activity: 
MVPA 71.37 54.47 47.40 5.04 0.016 9.74 0.004 0.192 0.999 − 15.90 0.198 0.41 − 23.97 0.004 0.70* − 8.07 0.830 0.20
Table 2.  Polynomial trends and pairwise comparisons for Irisin and Physical activity (ANOVA adjusted by 
covariates participants’ age and years of education). Abbreviations: HC, Healthy controls normal-weight; OB, 
Obesity; MO, Morbid-Obesity; |d|: Cohen’s-d. * Moderate to high effect size (|d| > 0.50). |d|: Cohen’s-d.  
* Moderate to high effect size (|d| > 0.50). Results include Bonferronis-correction for multiple comparisons.
Figure 1. Radar-chart for the distribution of the mean levels of irisin, activity and IGT-total measure in 
the three groups of weight (Z-scores). * Radar chart displays multivariate results in a two-dimensional chart, 
representing different axes for each category/group starting from the same point (center of the graphic) and 
extending outward from the center. Each color-line represents a different variable, and the line size drawn 
connecting the data to each axis represents the relative magnitude of the variable for the group. So, this graph 
displays what groups-observations are most similar/different and the connected pattern allows seeing the 
relative position of each group compared to others. To plot z-scores instead of raw-scores each metric gets equal 
weight and to simplify the interpretation.
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However, our results might indicate that the positive effects of physical activity on cognition would not be 
mediated by the action of irisin. Elevated levels of irisin were associated with disruption in cognitive flexibility 
performance and inhibition response in healthy controls and with disruption of decision making capacity in 
OB. Recent studies have been focusing on irisin as a potential treatment for obesity48,49. However, according to 
these results a potential cognitive effect of irisin might be considered when thinking about its therapeutic use. 
Nevertheless, we should keep in mind that this is a correlation study. Thus, future studies should confirm this 
hypothesis.
Although it is currently unknown whether irisin can cross the blood-brain barrier and whether irisin may 
function as a messenger between the skeletal muscle or adipose tissue and brain, previous studies have demon-
strated, for example, that peripheral administration of irisin is able to reduce blood pressure induced by sympa-
thetic out-flow31. From a neuropsychological perspective, the effects of irisin on executive functions might be 
explained by its action on some neurotransmitters, such as GABA and BDNF29. Irisin has recently been detected 
in the cerebellar Purkinje cells29, specifically in GABAergic cells. Although until now it has not been detected in 
other brain regions, this study points to a novel cerebral pathway that might also be implicating more cortical 
regions. Dysfunction of the GABAergic system may contribute to cognitive impairment in humans. Specifically, 
individuals with Alzheimer’s disease have decreased cerebral GABA in the brain and CSF50. Furthermore, GABA 
levels in human CSF decrease with aging51, which has been associated with cognitive impairment. According to 
these studies, the expression of irisin in the GABAergic brain cells might, to some extent, explain its effects on the 
central nervous system-mediated functions.
From a molecular perspective, the effects of irisin in the prefrontal-related cognitive functions might be medi-
ated by its association with the PPARγ coactivator-1 α (PGC1α ). As explained above the effects of irisin are medi-
ated by its action on the expression of UCP1, regulated by PGC1α 19. Specifically, higher expression of PGC1α 
is associated with higher levels of irisin. PGC1α is the main transcriptional regulator of mitochondrial func-
tion, associated with neurological deficits and cerebral anomalies52,53. Of interest, it has been demonstrated that 
PGC1α deficient mice show a significant brain deficiency54. In humans, genetic mutations on genes that affect 
mitochondrial functions have been found to contribute to the pathogenesis of neurodegenerative diseases such 
Adjusted means Factor Trends Pairwise-comparisons: mean differences
HC OB MO Group Linear Quadratic OB vs HC MO vs HC MO vs OB
n = 49 n = 21 n = 44 F(2;109) p CE p CE p MD p |d| MD p |d| MD p |d|
STROOP Interference 2.52 − 1.61 1.27 2.05 0.348 − 0.89 0.442 2.86 0.132 − 4.13 0.173 0.45 − 1.25 0.583 0.19 2.88 0.436 0.46
WCST
Total 
corrects 64.02 67.49 69.22 1.25 0.497 3.68 0.119 − 0.71 0.850 3.48 0.571 0.30 5.20 0.316 0.43 1.73 0.815 0.11
Total errors 30.13 36.38 34.13 0.47 0.692 2.83 0.454 − 3.47 0.676 6.25 0.571 0.29 4.01 0.583 0.18 − 2.25 0.815 0.08
Conceptual 
answers 54.76 56.65 60.17 0.88 0.555 3.82 0.224 0.66 0.857 1.90 0.759 0.11 5.41 0.398 0.31 3.51 0.815 0.16
Categories 
completed 4.64 4.43 4.64 0.13 0.881 0.00 0.997 0.18 0.774 − 0.22 0.759 0.12 0.00 0.997 0.01 0.22 0.815 0.09
IGT Total 31.73 − 0.81 3.40 11.24 0.001 − 20.04 <0.001 15.00 0.041 − 32.5 0.001 1.28* − 28.3 0.001 1.20* 4.21 0.815 0.19
Table 3.  Polynomial trends and pairwise comparisons for neuropsychological variables: ANOVA adjusted 
by the covariates participants’ age and years of education. Abbreviations: HC, healthy controls normal-
weight; OB, Obesity; MO, Morbid-Obesity. SCWT, Stroop Color and Word Test; WCST, Wisconsin Card 
Sorting Test; IGT, Iowa Gambling Task; Conc.answers, conceptual answers; Cat.complet., categories completed. 
|d|: Cohen’s-d. * Moderate to high effect size (|d| > 0.50). Results include Bonferroni’s-correction for multiple 
comparisons.
HC (n = 49) OB (n = 21) MO (n = 44)
Activity Irisin Activity Irisin Activity Irisin
r p r p r p r p r p r p
STROOP Interference − 0.081 0.594 − 0.228* 0.128 − 0.070 0.781 0.169 0.501 0.311* 0.078 − 0.038 0.835
WCST
Total corrects 0.223* 0.136 0.033 0.828 − 0.332* 0.179 0.170 0.500 0.154 0.392 0.088 0.624
Total errors − 0.056 0.711 0.233* 0.119 0.136 0.591 0.159 0.530 − 0.057 0.754 − 0.148 0.410
Conceptual answers 0.193 0.200 − 0.072 0.632 − 0.315* 0.203 − 0.091 0.719 0.150 0.405 0.143 0.426
Categories completed 0.157 0.299 − 0.204* 0.173 − 0.335* 0.175 − 0.083 0.743 0.157 0.384 0.012 0.948
IGT Total − 0.283* 0.056 0.151 0.317 0.491* 0.038 − 0.194 0.440 − 0.293* 0.098 − 0.335* 0.057
Table 4. Partial correlations (adjusted by the covariates age and years of education) between cognitive 
variables, physical activity and irisin. HC, healthy control normal-weight; CO-over., control over-weight; OB, 
Obesity; MO, Morbid-Obesity. Activity: MVPA score. SCWT, Stroop Color and Word Test; WCST, Wisconsin 
Card Sorting Test; IGT, Iowa Gambling Task. * Bold: moderate to high effect size for correlation (|R| > 0.20). 
Correlation matrix includes Bonferroni’s correction for multiple comparisons.
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as dementia55,56. In particular, genes that are expressed in response to PGC-1α are under-expressed in Parkinson’s 
disease and Lewy body disease patients56. It has also been suggested that enhancement of PGC-1α by dietary 
treatment might benefit cognitive function and synaptic plasticity in Alzheimer’s disease by preventing Aβ pro-
duction in the brain53,55,57. This positive correlation between PGC-1α and cognition was not observed in our 
study. One possible explanation could be that increased irisin levels in obese subjects result from physiological 
compensatory mechanisms that may involve decreased sensitivity to irisin or an attempt to increase glucose 
sensitivity28.
This study has several strengths, including the large sample size. Biological approaches, as applied in the pres-
ent study, are an additional level of analysis on top of neuropsychological assessment, which provides a practical 
tool for the study of executive processes. Additionally, our study was specifically designed to comprehensively 
test the executive dysfunction in obese and morbidly obese subjects by using three well validated executive 
tasks. However, the results of this study should be interpreted in the context of some limitations. First, meas-
ures of intelligence quotient (IQ) were not considered, which might have influenced executive performance. 
Nonetheless, years of education, as a measure of cognitive capacity have been considered in the statistical analysis. 
Second, only females were included in the study, making the results not applicable to males. Replication of these 
results with a group including males should be considered. Future studies should also consider including further 
decision-making, inhibition response and cognitive flexibility tasks in order to shed more light on the mecha-
nisms underlying the executive functions profile in obesity. Moreover, the cross-reactivity of the ELISA immu-
noassay on detecting irisin FNDC5 precursor at circulating level should be taken into account28. Also, although 
we have used multivariate methods to control the potential biases due to potential confounder variables58, the 
control group is not matched for age and education. Future studies should replicate this study with a control 
group matched for age and education. Additionally, results reflect moderate to high effect size of correlations 
between levels of irisin, physical activity and cognition. Future studies should further explore these associations 
with bigger sample populations to check for p-value statistical significances. Finally, altered irisin levels have been 
associated with fatty liver, renal, and autoimmune diseases59. Future studies including these variables should also 
be considered.
In summary, our results provide novel information regarding the executive pattern of obesity and the influ-
ence of the physical activity and irisin on the cognitive profile. This study is particularly timely given the impor-
tant public-health impact of obesity and the potential significance of accurately-defined biological variables that 
are associated. Efforts should focus on determining new biomarkers in order to accelerate the detection of poten-
tial drug targets and the implementation of new therapeutic approaches. According to our results, the undesirable 
effects of irisin on cognition should be considered before using it as a target for the treatment of these extreme 
eating/weight conditions.
Material and Methods
Sample. Seven centers, all involved in the CIBERobn Spanish Research Network, participated: the Eating 
Disorders Unit (Department of Psychiatry, University Hospital of Bellvitge-IDIBELL, Barcelona), the Department 
of Endocrinology at the University Hospital of Santiago (Santiago de Compostela); the Department of Diabetes, 
Endocrinology and Nutrition (Clinic University Hospital Virgen de Victoria, Málaga); the Department of Endocrinology 
and Nutrition (University of Navarra, Pamplona); the Diabetes, Endocrinology and Nutrition Department, Biomedical 
Research Institute of Girona (IdIBGi-Doctor Josep Trueta Hospital, Girona); the IMIM (Hospital del Mar Medical 
Research Institute, Barcelona) and the Department of Basic Psychology, Clinic and Psychobiology (University Jaume I, 
Castelló). Enrolment into the study took place between January 2010 and September 2013.
One hundred and fourteen participants were included, distributed along the BMI continuum: 21 obese sub-
jects (BMI = 30–39.9 kg/m2), 44 morbid obese subjects (BMI ≥ 40 kg/m2) and 49 healthy controls (BMI = 18.97–
24.61 kg/m2). BMI was calculated as the body mass divided by the squared height of the subject. Height was 
calculated using a stadiometer. All participants were female, aged between 18 and 60 years and spoke Spanish as their 
first language. Participants were informed about the research procedures and gave informed consent in writing. 
Procedures were approved by the Ethical Committee of each of the aforementioned institutions (Ref. 048/10; 
307/06; 2010/3914/I; 110/2010). The methods were carried out in accordance with the approved guidelines.
The exclusion criteria were: (1) History of chronic medical illness or neurological condition that might affect 
cognitive function; (2) Head trauma with loss of consciousness for more than 2 min, learning disability or mental 
retardation; (3) Use of psycho-active medications or drugs (4) Being male; (5) Age under 18 or over 60 (to discard 
neuropsychological deficits associated with age); (6) Having diabetes type I or II. (7) Obese patients who have 
comorbid binge eating disorder (DSM-IV criteria60). Healthy controls were recruited through several sources 
including word-of-mouth and advertisements in the local university. Prior to assessment, HC were asked about 
lifetime or current presence of an eating disorders or obesity. The lifetime history of health or mental illnesses 
profile was based on the general health questionnaire GHQ-2861.
Neuropsychological assessment. As described in a previous study6, all participants underwent a compre-
hensive neuropsychological and clinical assessment. The neuropsychological tests were selected to cover various 
aspects of executive functions including decision making, response inhibition, strategic planning and cognitive 
flexibility and were administered by a trained psychologist in a single session and in a randomized order. All par-
ticipants were assessed with the following neuropsychological tests: (a) Wisconsin Card Sorting Test (WCST)62, 
(b) Stroop Color and Word Test (SCWT)63 and (c) Iowa Gambling Task (IGT)64.
Wisconsin Card Sorting Test. The WCST is a classical measure of planning capacity, cognitive flexibility, capacity 
of shifting among stimulus, and control of impulsive responses not aimed at achieving an objective. Subjects have 
to match a target card with one of four category cards: a single red triangle, two green stars, three yellow crosses, 
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and 4 blue circles. Cards might be matched by color, number, or shape. After each trial a feedback is given to the 
participant, indicating if they have correctly matched the card. However, along the task the classification rule 
is unpredictably changing. The test ends when the participant has completed 6 categories or 128 trials. For the 
purpose of this study the following measures of the test were considered: Total corrects responses, Total errors, 
Conceptual answers, and Total Categories completed.
Stroop Color and Word Test. This paper and pencil test has shown adequate reliability and construct validity 
for the assessment of inhibition and switching skills. The SCWT measures interference control, flexibility and 
attention. The task included three pages: (1) a page with color words printed in black ink; (2) a page with “Xs” 
printed in color; (3) a page with names of colors printed in an incongruent color (i.e. word “blue” printed in red 
ink). Participants have 45 seconds to read as many words as possible in the first page and name the ink in pages 2 
and 3. Three scores are obtained after task completion: number of words (W) (page 1), number of colors named 
“X” (C) (page 2) and number of color-named words (CW) (page 3). With these scores, the CW estimated (CW′ ) 
is calculated by using the formula: CW′ = (W* C)/(W + C). An additional “interference score” is obtained with 
the formula: Interference = CW-CW′ . This is the main variable and higher scores in this variable indicate better 
capacity of inhibition response.
Iowa Gambling Task. This computer task evaluates decision-making, risk and reward and punishment value. 
The subject has to select 100 cards from four decks (A, B, C and D). After each card selection an output is given: 
gain or a gain and loss of money. Two decks (A and B) are not advantageous as the final loss is higher than the 
final gain. Decks C and D, however, are advantageous since the punishments are smaller. The final objective of 
the task is to make the most of profit and gain as much money as possible. This test is scored by subtracting the 
amount of cards selected from decks A and B from the amount of cards selected from decks C and D. Higher 
results point to better performance while negative results point to preference for the not advantageous decks.
Physical Activity assessment. Physical Activity was evaluated with Actiwatch AW7 (Actiwatch AW7; 
CamNtech Ltd, Cambridge Neurotechnology, Cambridge, UK), a small (3963269 mm), light-weight (10.5 g) 
accelerometer that measures activity. The Actiwatch is worn on the non-dominant wrist for 6 days (4 week-
days and 1 weekend), from 00:00 hr on day 1 to 00:00 hr on day 7. Physicacl activity data was calculated in the 
form of activity counts in a 1-minute epoch length over 24 hours. The counts represent the peak intensity of 
the movement detected by the Actiwatch AW7. Only the data between 7:00 hr and 23:00 hr is analyzed; a data 
reduction procedure that has been recommended and conducted in previous studies65,66. No detected move-
ment for 10 or more consecutive epochs (10 minutes) is considered as missing (seen as implausible counts or as 
periods during which the participant is sleeping). In addition, a minimum of 4 days of wear is used as criterion 
to accept the case. This is the lower recommended minimum to accurately estimate daily PA in adults67. Upon 
analysis of the data, there were no cases of 4 or less days of wear. The Actiwatch 7 software (CamNtech Ltd) is 
used to extract the data. For the purpose of this study the time in Moderate-Vigorous Physical Activity (MVPA) 
was considered. The average amount of time during the day spent in MVPA was calculated using an algorithm 
proposed by Heil67. Employing the activity monitor Actical (Mini Mitter Co., Inc., Bend, OR), another Actiwatch 
produced by the same manufacturer, which was placed on the ankle, hip and wrist, Heil67 developed algorithms 
to predict activity energy expenditure (AEE) in children and adults. To obtain the cut point for MVPA, the for-
mula, AEE = 0.02013 + (1.282E-5) × HAC (elaborated for wrist worn accelerometers) was used. This yielded a 
cut point of 848 counts x min−1. This value predicts a PA intensity of 3 MET, which corresponds to a brisk 
walk. The algorithm to predict AEE in children has been used in a previous study to identify MVPA from the 
wrist-worn Actiwatch AW4 (CamNtech Ltd, Cambridge Neurotechnology, Cambridge, UK), an earlier version of 
the Actiwatch AW767. This method has been previously used in obese population68.
Irisin quantification method. Blood samples from overall participants were obtained under basal con-
ditions after a 12-h overnight fast. EDTA-plasma and serum of specimen were separated from whole blood and 
immediately frozen at − 80° C until assay.
The quantitative measurement of irisin in human plasma samples was performed using a commercial 
enzyme-linked immunosorbent assay (ELISA) kit directed against amino acids 31–143 of the FNDC5 protein 
(Irisin ELISA Kit EK-067-52; Phoenix Pharmaceuticals, INC, CA) according to the manufacturer’s instruc-
tions. Absorbance from each sample was measured in duplicate using a spectrophotometric microplate 
reader at wavelength of 450 nm (Versamax Microplate Reader; Associates of Cape Cod Incorporated, East 
Falmouth, MA).
Statistical analysis. Analyses were carried out with SPSS21 for Windows. First, analysis of variance 
(ANOVA) valued the association between the diagnosis subtype and the neurocognitive measures. Due the ordi-
nal scale for the weight measure (HC, OB and MOB), ANOVA included polynomial contrasts to explore the 
presence of trends (linear and quadratic). In addition, considering the importance of age and education on the 
cognitive performance, these two variables were included as covariates in the ANOVA procedures. The effect 
size for each pairwise comparison was valued through Cohen’s-d coefficient (moderate effect size was considered 
for |d| > 0.50 and high for |d| > 0.80). Second, the association between physical activity and irisin with cognitive 
outcomes was assessed with partial correlations, also adjusted by covariates patients’ age and years of academic 
studies. Due the strong association between R-coefficients and significant test (only large R-coefficients achieve 
significant results in small size samples while small R-coefficients achieve significant results in large samples), 
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correlations were interpreted as relevant based on their sample size (moderate effect-size was considered for 
|R| ≥ 0.20 and good effect-size for |R| ≥ 0.2569,70.
Due the multiple statistical tests, potential increases in Type I error was controlled through Bonferroni’s method.
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